Loading
A phase 2/3 trial of Izalontamab brengitecan, Carboplatin, Cisplatin in non-small-cell lung cancer and small-cell lung cancer, run by Bristol-Myers Squibb, now recruiting.
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01) is a phase 2/3 interventional study registered as NCT07100080 by Bristol-Myers Squibb, with 500 participants planned, started 2025-11-05 and due to reach its primary completion in 2028-12-15. Interventions recorded: Iza-bren, Carboplatin, Cisplatin, Pemetrexed. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Izalontamab brengitecan, Pemetrexed, Bristol Myers Squibb, EGFR-mutated non-small-cell lung cancer.
Shares Izalontamab brengitecan, Pemetrexed, EGFR-mutated non-small-cell lung cancer, Cisplatin.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Cisplatin, Carboplatin.
Shares Izalontamab brengitecan, Pemetrexed, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer.
Shares Pemetrexed, Bristol Myers Squibb, Cisplatin, Carboplatin.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Cisplatin, Carboplatin.
Shares Pemetrexed, Bristol Myers Squibb, Cisplatin, Carboplatin.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Carboplatin, Antibody-drug conjugate (ADC).